Engineered endocrine objects tolerate hypoxia in macroencapsulation devices and enable subcutaneous engraftment in diabetic mice

Islet encapsulation has been pursued for decades as a potential immunosuppression-free transplantation strategy to treat type 1 diabetes (T1D). The encapsulation device protects islets from immune cell-contact mediated killing, but it also prevents vascular penetration and intra-islet vascularization, leading to poor mass transfer and islet central necrosis. In healthy pancreas, islets with sizes > ~40 μm are vascularized while non-islet endocrine cell clusters below ~40 μm exist without internal capillaries. Here, we developed scalable and reproducible engineered endocrine objects (EEOs) as small as ~47 μm by mesh-induced fragmentation of native islets, followed by a recovery culture. Under hypoxic culture condition (1% O2 for 24 hours), EEOs showed enhanced viability of >90%, compared to 49% for the native islet control. With a flat, thin (0.5-mm-thick) alginate-based macroencapsulation device, rat EEOs at a marginal dose of 300 islet equivalents (IEQ) achieved glycemic control for over 5 weeks in the challenging, hypoxic subcutaneous space of immunocompetent diabetic mice. The engrafted mice displayed near-physiological glycemic profiles upon glucose challenge, and the retrieved EEOs showed enhanced viability with significantly reduced central necrosis compared with native islets. Overall, engineering hypoxia-resistance into cellular products mitigates intrinsic constraints of encapsulation devices, offering a promising strategy for convenient, immunosuppression-free subcutaneous islet transplantation.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.10.765512
Primary Topic
Pancreatic function and diabetes
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Engineered endocrine objects tolerate hypoxia in macroencapsulation devices and enable subcutaneous engraftment in diabetic mice

James Arthur Flanders, Kecheng Wang, Phuong Le Tran, Kento Okada et al.
bioRxiv (Cold Spring Harbor Laboratory)
Pancreatic function and diabetes
preprint

Engineered endocrine objects tolerate hypoxia in macroencapsulation devices and enable subcutaneous engraftment in diabetic mice

James Arthur Flanders, Kecheng Wang, Phuong Le Tran, Kento Okada, Minseok Lee, Min Jin, Jerry Deng, Bo Wang, Minglin Ma
preprint en

Abstract

Islet encapsulation has been pursued for decades as a potential immunosuppression-free transplantation strategy to treat type 1 diabetes (T1D). The encapsulation device protects islets from immune cell-contact mediated killing, but it also prevents vascular penetration and intra-islet vascularization, leading to poor mass transfer and islet central necrosis. In healthy pancreas, islets with sizes > ~40 μm are vascularized while non-islet endocrine cell clusters below ~40 μm exist without internal capillaries. Here, we developed scalable and reproducible engineered endocrine objects (EEOs) as small as ~47 μm by mesh-induced fragmentation of native islets, followed by a recovery culture. Under hypoxic culture condition (1% O2 for 24 hours), EEOs showed enhanced viability of >90%, compared to 49% for the native islet control. With a flat, thin (0.5-mm-thick) alginate-based macroencapsulation device, rat EEOs at a marginal dose of 300 islet equivalents (IEQ) achieved glycemic control for over 5 weeks in the challenging, hypoxic subcutaneous space of immunocompetent diabetic mice. The engrafted mice displayed near-physiological glycemic profiles upon glucose challenge, and the retrieved EEOs showed enhanced viability with significantly reduced central necrosis compared with native islets. Overall, engineering hypoxia-resistance into cellular products mitigates intrinsic constraints of encapsulation devices, offering a promising strategy for convenient, immunosuppression-free subcutaneous islet transplantation.

bioRxiv (Cold Spring Harbor Laboratory)
Cornell University (US)
National Institute of Diabetes and Digestive and Kidney Diseases
Good health and well-being
Pancreatic function and diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon